The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.

Detroit Medical Center, Detroit, MI. <>
Journal of cardiac failure (Impact Factor: 3.07). 05/2010; 16(5):419-31. DOI: 10.1016/j.cardfail.2009.12.021
Source: PubMed

ABSTRACT Hypervolemia and hyponatremia resulting from activation of the neurohormonal system and impairment of renal function are prominent features of decompensated heart failure. Both conditions share many pathophysiologic and prognostic features and each has been associated with increased morbidity and mortality. When both conditions coexist, therapeutic options are limited.
This review presents a concise digest of the pathophysiology, clinical significance, and pharmacological therapy of hyponatremia complicating heart failure with a special emphasis on vasopressin antagonists and their aquaretic effects in the absence of neurohormonal activation along with their ability to correct hyponatremia.
Hypervolemia and hyponatremia share many pathophysiologic and prognostic features in heart failure. Vasopressin antagonists provide a viable option for their management and a potentially unique role when both conditions coexists.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Among amino acids, arginine is important in human physiology because it plays an important role in cardiovascular and depression problems. In this paper the behavior of arginine as a ligand toward cadmium(II) [Cd(II)] in two different ionic media: 1.00 mol·dm−3 NaCl and NaClO4, is studied. Knowledge of the species formed between Cd(II) and arginine in a wide concentration range is useful also in biology. This system was investigated using two different methods in two ranges of hydrogen ion concentration. In acidic solutions, electromotive force measurements are performed using glass and Cd amalgam electrodes. In basic solutions, polarography was used and the shift of the half wave potential was measured as a function of the ligand concentration. The experimental data obtained in NaCl solutions are explained by assuming the formation of the species [CdL], [CdHL], [CdL2], [CdHL2] and [CdH2L2]. The data obtained in NaClO4 solutions are explained by assuming the formation of the species [CdL], [CdHL], and [CdH2L2]. In both cases the stability constants are reported.
    Journal of Solution Chemistry 05/2013; 42(4). DOI:10.1007/s10953-013-9988-7 · 1.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The present review analyses the mechanisms relating heart failure and hyponatremia, describes the association of hyponatremia with the progress of disease and morbidity/mortality in heart failure patients and presents treatment options focusing on the role of arginine vasopressin (AVP)-receptor antagonists. Hyponatremia is the most common electrolyte disorder in the clinical setting and in hospitalized patients. Patients with hyponatremia may have neurologic symptoms since low sodium concentration produces brain edema, but the rapid correction of hyponatremia is also associated with major neurologic complications. Patients with heart failure often develop hyponatremia owing to the activation of many neurohormonal systems leading to decrease of sodium levels. A large number of clinical studies have associated hyponatremia with increased morbidity and mortality in patients hospitalized for heart failure or outpatients with chronic heart failure. Treatment options for hyponatremia in heart failure, such as water restriction or the use of hypertonic saline with loop diuretics, have limited efficacy. AVP-receptor antagonists increase sodium levels effectively and their use seems promising in patients with hyponatremia. However, the effects of AVP-receptor antagonists on hard outcomes in patients with heart failure and hyponatremia have not been thoroughly examined.
    World Journal of Cardiology (WJC) 09/2013; 5(9):317-328. DOI:10.4330/wjc.v5.i9.317 · 2.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the present study was to clarify the mechanisms mediating the effect of a glucagon-like peptide-1 (GLP-1) mimetic on solute-free water excretion in rats. GLP-1 mimetic (exenatide, 0.05-5.0 nmol/kg, i.m.) alone and with a V2 -antagonist (15 nmol/kg, i.p.) or vasopressin (0.01 nmol/kg, i.m.) was injected into control and water-loaded (water 10-50 mL/kg, p.o., or 0.6% NaCl 50 mL/kg, i.p.) rats to evaluate the role of collecting duct water permeability in the hydrouretic effect. Urinary PGE2 excretion and the effect of diclofenac and an antagonist of the GLP-1 receptors (0.15 μmol/kg, i.p.) on exenatide action were assessed. The hydrouretic effect of exenatide was equivalent following oral or intraperitoneal water loading, and it was proportional to the volume of water administered. Injection of exenatide, under conditions of maximal decrease in collecting duct water permeability (V2 -antagonist administration in water-loaded rats), additionally stimulated solute-free water formation. The GLP-1 receptor antagonist weakened the hydrouretic action of exenatide. Urinary PGE2 excretion increased following water loading (47 ± 6 ng/kg vs. 24 ± 4 ng/kg over a 30 min period), and it was enhanced as a result of an additional exenatide injection (69 ± 10 ng/kg). Diclofenac and vasopressin delayed the hydrouretic effect of exenatide. The effect of exenatide on solute-free water clearance in water-loaded rats is presumably mediated by stimulation of PGE2 secretion and reinforcement of tubular fluid influx from the proximal tubule to the distal segment of the nephron and collecting duct. This article is protected by copyright. All rights reserved.
    Clinical and Experimental Pharmacology and Physiology 05/2013; 40(8). DOI:10.1111/1440-1681.12119